To tackle the crisis of AMR, we need to fully understand it. The pharmaceutical industry routinely collects surveillance data to monitor susceptibility of clinical isolates to marketed products, or to fulfil regulatory approval requirements for new products. The open sharing of these data through a single platform will enable researchers to:
- Identify global, regional and local changes in resistance rates of pathogens
- Outbreaks of resistant pathogens
- Recognize the emergence of new resistance mechanisms
- Detect trends in multi-drug resistance by analyzing data over time
- Provide reliable, global, regional in vitro susceptibility data
- Help inform national and international policy, and antibiotic stewardship
- Allow modelling of future resistance trends
Our hope is that the research projects enabled by this platform will further advance understanding, inform decision-making and drive policy changes in the medical community, global organizations such as the United Nations and the World Health Organisation, and wider society.
This AMR Register has been developed by Vivli, with a grant awarded by Wellcome, in support of these aims.